Payment overview · 2025
General Payments
$629.35
24 reported records · 10 companies
Healthcare provider profile · identity verified
Paul E Shepard, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CYPRESS, TX · NPI 1467440131
Verified facts
What the public records show
CMS Open Payments records show Paul E Shepard, M.D. received $629.35 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.98 | 33.8% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.75 | 17.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.88 | 9.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.77 | 9.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.42 | 6.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.29 | 5.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.63 | 5.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.58 | 4.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.64 | 4.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.41 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $629.35 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $212.98 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $110.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $89.20 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.77 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 76 |
| Metformin Hcl | Metformin Hcl | 200 | 64 |
| Losartan Potassium | Losartan Potassium | 176 | 61 |
| Lisinopril | Lisinopril | 148 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 41 |
| Mounjaro | Tirzepatide | 116 | 25 |
| Sertraline Hcl | Sertraline Hcl | 112 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 41 |
| Simvastatin | Simvastatin | 103 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 34 |
| Ezetimibe | Ezetimibe | 97 | 37 |
| Ozempic | Semaglutide | 92 | 20 |
| Omeprazole | Omeprazole | 86 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 33 |
| Alprazolam | Alprazolam | 82 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 29 |
| Gabapentin | Gabapentin | 73 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 33 |
| Lorazepam | Lorazepam | 70 | 13 |
| Montelukast Sodium | Montelukast Sodium | 70 | 28 |
| Allopurinol | Allopurinol | 67 | 20 |
| Synthroid | Levothyroxine Sodium | 66 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 26 |
| Jardiance | Empagliflozin | 62 | 12 |
| Donepezil Hcl | Donepezil Hcl | 61 | 19 |
| Trazodone Hcl | Trazodone Hcl | 61 | 19 |
| Carvedilol | Carvedilol | 56 | 19 |
| Tramadol Hcl | Tramadol Hcl | 55 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 22 |
| Furosemide | Furosemide | 54 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 45 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 15 |
| Meloxicam | Meloxicam | 49 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Metformin Hcl Er | Metformin Hcl | 41 | 14 |
| Potassium Chloride | Potassium Chloride | 41 | 18 |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 19 |
| Azelastine Hcl | Azelastine Hcl | 39 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 32 |
| Bupropion Xl | Bupropion Hcl | 34 | 11 |
| Atenolol | Atenolol | 33 | 11 |
| Baclofen | Baclofen | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | 11 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Famotidine | Famotidine | 27 | 11 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 17 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Prednisone | Prednisone | 18 | 14 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Diazepam | Diazepam | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $629.35 · 24 records | Novo Nordisk Inc | BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, INSPIRE, JARDIANCE, LINZESS, Ozempic, PREVNAR 20, Rybelsus, TRINTELLIX, VOQUEZNA, VRAYLAR, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error